Published in J Invasive Cardiol on December 01, 2000
Identification of the heparin-binding domains of the interferon-induced protein kinase, PKR. FEBS J (2005) 0.90
Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1). J Biol Chem (2005) 0.88
Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. Heart (2004) 0.82
Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. Tex Heart Inst J (2009) 0.80
Between-subject variability: should high be the new normal? Eur J Clin Pharmacol (2014) 0.78
Unstable angina and non-ST-segment elevation myocardial infarction: perspectives on combination therapy. Tex Heart Inst J (2001) 0.75
Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcomes. J Am Coll Cardiol (1995) 4.10
Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med (2000) 3.70
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA (1997) 3.51
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med (2001) 2.83
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J (2002) 2.49
Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation (2001) 2.43
Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996. Circulation (1997) 2.15
Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation (2000) 2.05
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90
Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation (1991) 1.83
Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol (1998) 1.79
Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation (1994) 1.76
Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol (1993) 1.70
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management. Catheter Cardiovasc Interv (2001) 1.69
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation (2001) 1.58
Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. J Am Coll Cardiol (1990) 1.57
Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn (1996) 1.54
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation (2001) 1.54
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation (1989) 1.54
The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1991) 1.48
Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction. Cathet Cardiovasc Diagn (1997) 1.47
Comparison of acute results of prophylactic intraaortic balloon pumping with cardiopulmonary support for percutaneous transluminal coronary angioplasty (PCTA) Cathet Cardiovasc Diagn (1998) 1.44
Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol (1995) 1.43
Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Cathet Cardiovasc Diagn (1996) 1.43
Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trail. J Am Coll Cardiol (1995) 1.40
Percutaneous triple-valve balloon valvuloplasty in a pregnant woman. Cathet Cardiovasc Diagn (1991) 1.39
Efficacy of angioscopy in determining the effectiveness of intracoronary urokinase and TEC atherectomy thrombus removal from an occluded saphenous vein graft prior to stent implantation. Cathet Cardiovasc Diagn (1995) 1.39
Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting. Ann Emerg Med (1998) 1.39
Successful reversal of cardiogenic shock precipitated by saphenous vein graft distal embolization using aspiration thrombectomy. Cathet Cardiovasc Diagn (1994) 1.38
Relation of stenosis morphology and clinical presentation to the procedural results of directional coronary atherectomy. Circulation (1991) 1.38
A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation (1992) 1.32
A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation (1989) 1.30
Postinfarction left ventricular pseudoaneurysm. Clin Cardiol (1997) 1.22
Myocarditis and cardiomyopathy. Am Heart J (1984) 1.22
Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation (1994) 1.21
Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. Ann Intern Med (1988) 1.21
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J (2001) 1.20
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 1.15
Angioplasty in total coronary artery occlusion: experience in 76 consecutive patients. J Am Coll Cardiol (1985) 1.15
Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol (2001) 1.13
Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. Am J Cardiol (1991) 1.12
Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol (2001) 1.11
Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. J Am Coll Cardiol (1997) 1.11
Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol (1993) 1.10
Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J (1997) 1.09
Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J (1998) 1.07
Glidewire treatment of resistant coronary occlusions. Cathet Cardiovasc Diagn (1993) 1.07
A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation (1992) 1.06
A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation (1987) 1.06
Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol (1999) 1.05
Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J (1998) 1.04
Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol (1998) 1.03
A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. J Am Coll Cardiol (1997) 1.03
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation (1995) 1.03
Percutaneous transluminal angioplasty of left internal mammary artery grafts. Am J Cardiol (1985) 1.02
Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial. Am Heart J (1991) 1.02
Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). Am J Cardiol (1994) 1.02
Application of a new phased-array ultrasound imaging catheter in the assessment of vascular dimensions. In vivo comparison to cineangiography. Circulation (1990) 1.02
Incidence and angiographic predictors of side branch occlusion following high-pressure intracoronary stenting. Am J Cardiol (1997) 1.02
Abciximab readministration: results of the ReoPro Readministration Registry. Circulation (2001) 1.01
Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation (1993) 0.99
Effects of left bundle branch block on the events of the cardiac cycle. Acta Cardiol (1988) 0.99
Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. Am J Cardiol (1991) 0.98
Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. Circulation (1994) 0.98
Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction. Am J Cardiol (2001) 0.97
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation (1988) 0.96
Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. J Am Coll Cardiol (1990) 0.95
Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol (1995) 0.94
Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation (1996) 0.93
Apical hypertrophic cardiomyopathy. Am Heart J (1983) 0.92
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation (1994) 0.92
Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation (2001) 0.92
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation (1998) 0.91
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. Circulation (1988) 0.91
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol (1999) 0.91
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. J Am Coll Cardiol (1989) 0.90
Role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol (2000) 0.90
Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation (2000) 0.90
Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation (1999) 0.90
Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. J Am Coll Cardiol (2001) 0.89
Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol (1990) 0.89
Usefulness of technetium-99m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction. Am J Cardiol (1998) 0.87
A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol (1998) 0.87
The heart in diabetes. West J Med (1984) 0.85
Intercenter variability in outcome for patients treated with direct coronary angioplasty during acute myocardial infarction. Am Heart J (1998) 0.85
Efficacy of abciximab readministration in coronary intervention. Am J Cardiol (2000) 0.84
Clinical and angiographic outcomes in patients with previous coronary artery bypass graft surgery treated with primary balloon angioplasty for acute myocardial infarction. Second Primary Angioplasty in Myocardial Infarction Trial (PAMI-2) Investigators. J Am Coll Cardiol (2000) 0.84
PET perfusion and vasodilator function after angioplasty for acute myocardial infarction. J Nucl Med (1997) 0.83
Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol (1996) 0.83
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol (2001) 0.83